{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Pancreatic+%28Ductal%29+Adenocarcinoma", "query": { "condition": "Metastatic Pancreatic (Ductal) Adenocarcinoma" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 189, "total_pages": 19, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Pancreatic+%28Ductal%29+Adenocarcinoma&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-23T10:22:02.859Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00471146", "title": "Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Pancreatic Ductal" ], "interventions": [ { "name": "AG-013736", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 630, "start_date": "2007-07", "completion_date": "2010-11", "has_results": true, "last_update_posted_date": "2012-07-16", "last_synced_at": "2026-07-23T10:22:02.859Z", "location_count": 77, "location_summary": "Antioch, California • Corona, California • Glendora, California + 57 more", "locations": [ { "city": "Antioch", "state": "California" }, { "city": "Corona", "state": "California" }, { "city": "Glendora", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00471146" }, { "nct_id": "NCT04704154", "title": "A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "Regorafenib, (Stivarga, BAY73-4506)", "type": "DRUG" }, { "name": "Nivolumab (Opdivo)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 175, "start_date": "2021-02-03", "completion_date": "2024-03-29", "has_results": true, "last_update_posted_date": "2025-04-18", "last_synced_at": "2026-07-23T10:22:02.859Z", "location_count": 6, "location_summary": "Duarte, California • Aurora, Colorado • Tampa, Florida + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04704154" }, { "nct_id": "NCT00869050", "title": "Capecitabine and Temozolomide for Neuroendocrine Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroendocrine Tumors" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 41, "start_date": "2005-08", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2016-07-25", "last_synced_at": "2026-07-23T10:22:02.859Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00869050" }, { "nct_id": "NCT04005690", "title": "Targeted Pathway Inhibition in Patients With Pancreatic Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Locally Advanced Pancreatic Ductal Adenocarcinoma", "Metastatic Pancreatic Ductal Adenocarcinoma", "Stage II Pancreatic Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Unresectable Pancreatic Ductal Adenocarcinoma", "Borderline Resectable Pancreatic Ductal Adenocarcinoma", "Resectable Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Onvansertib", "type": "DRUG" }, { "name": "Azenosertib", "type": "DRUG" }, { "name": "Saruparib", "type": "DRUG" }, { "name": "Tremelimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2019-08-01", "completion_date": "2028-02-01", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-07-23T10:22:02.859Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT04005690" }, { "nct_id": "NCT05431270", "title": "Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer", "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "Mavrostobart (PT199)", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Gemcitabine + nab-Paclitaxel", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Carboplatin + Pemetrexed", "type": "DRUG" }, { "name": "Pembrolizumab + Carboplatin + Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Phanes Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2022-08-11", "completion_date": "2028-08", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-07-23T10:22:02.859Z", "location_count": 6, "location_summary": "Huntersville, North Carolina • Oklahoma City, Oklahoma • Nashville, Tennessee + 3 more", "locations": [ { "city": "Huntersville", "state": "North Carolina" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" }, { "city": "Webster", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05431270" }, { "nct_id": "NCT02677038", "title": "Olaparib in Treating Patients With Stage IV Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Adenocarcinoma", "Pancreatic Ductal Adenocarcinoma", "Stage IV Pancreatic Cancer AJCC v6 and v7" ], "interventions": [ { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2016-11-11", "completion_date": "2022-07-18", "has_results": true, "last_update_posted_date": "2024-10-01", "last_synced_at": "2026-07-23T10:22:02.859Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02677038" }, { "nct_id": "NCT06364696", "title": "A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "ASP4396", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2024-04-16", "completion_date": "2026-06-17", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-07-23T10:22:02.859Z", "location_count": 7, "location_summary": "Westwood, Kansas • Grand Rapids, Michigan • New York, New York + 4 more", "locations": [ { "city": "Westwood", "state": "Kansas" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Rochester", "state": "New York" }, { "city": "Irving", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06364696" }, { "nct_id": "NCT07089940", "title": "OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Locally Advanced Pancreatic Ductal Adenocarcinoma", "Metastatic Pancreatic Ductal Adenocarcinoma", "Stage II Pancreatic Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Myc Inhibitor OMO-103", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2026-01-27", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-03-23", "last_synced_at": "2026-07-23T10:22:02.859Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT07089940" }, { "nct_id": "NCT07217717", "title": "Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma (PDAC)" ], "interventions": [ { "name": "[18F]FAPI-74 PET/CT", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SOFIE", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2025-12-11", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-06-30", "last_synced_at": "2026-07-23T10:22:02.859Z", "location_count": 15, "location_summary": "Cerritos, California • Duarte, California • Irvine, California + 11 more", "locations": [ { "city": "Cerritos", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07217717" }, { "nct_id": "NCT04477343", "title": "A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma", "Pancreatic Cancer" ], "interventions": [ { "name": "SX-682", "type": "DRUG" }, { "name": "Nivolumab Injectable Product", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Rochester", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2020-11-23", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-07-23T10:22:02.859Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04477343" } ] }